ECHO 360

HOME
ADMIN

Scientific Program

Room A [English] Room B [Korean] Room C [Korean]

Time	Room A [English]
08:20-08:30	Opening and Course Introduction
08:30-09:50	New concepts in VHD in 2026 II
	Lifetime Management in SHD: Integrating Risk Control and Strategic Intervention Timing
	CCTA for Valve Intervention: New Standard or Selective Alternative?
	Structural Valve Deterioration: From Mechanisms to Clinical Impact
	Antithrombotic Management after TAVI
	When "Moderate" Is Not Benign: Rethinking Risk in Multivalvular VHD
	Panel Discussion
09:50-10:10	Coffee Break
10:10-11:00	Plenary Lectures
	CT at the Center of Structural Heart Intervention: From Patient Selection to Lifetime Management
	TAVI Today and Tomorrow: International Trends and Future Direction
	Discussion
11:00-12:20	Aortic Valve Disease: Current Strategies for Management and Unresolved Questions
	Imaging-Guided Decision Making in Aortic Stenosis and TAVI - What May Impact the Outcome?
	Structural Heart Echocardiography in Complex TAVR Procedures (Low Coronary Height and AR)
	Specific Anatomical Features in Patients in Asia - Leaflet Modifications for TAV-in-SAV
	Totally Endoscopic Aortic Valve Replacement with 3D Visualization: UMC's Experience
	Management of AR: Current Strategies and Unresolved Questions
	Panel Discussion
12:20-13:30	Luncheon Session
	Topic 1
	Topic 2
13:30-14:40	HEART TEAM AT WORK, Learn from Case: Tricuspid Regurgitation
	Patient Presentation and Imaging Analysis
	Discussion and Audience Interaction
	Anatomy and Mechanisms of Tricuspid Regurgitation: Imager's Point of View
	Tricuspid Valve Repair: Surgery or Transcatheter?: Surgeon's Point of View
	When and Where Does T-TEER and TTVR Fit in and More: Interventionist's Point of View
	Heart Team Discussion and Audience Interaction
	How Did Our Case End
	Heart Team Panels
14:40-15:00	Coffee Break
15:00-16:20	Essentials in Management of Tricuspid Regurgitation
	TR Assessment: Limitations of Current Metrics and Emerging Solutions
	Patient Selection for Transcatheter Therapies for TR: Who Gets What
	Tricuspid TEER Procedure: Techniques, Tips, and Pitfalls
	Tricuspid Valve Imaging for T-TEER: Optimal Imaging Guidance Using 3D TEE & ICE
	Challenging Candidates for T-TEER and New Solutions
	Panel Discussion
16:20-17:40	2026 SHD in Asia: New Innovations in SHD Management
	Advanced Valve Function Analysis Using 3D Echocardiography: State of the Art and What Lies Ahead?
	Minimal Invasive & Robotic Surgery in Interventional Era
	Transcatheter Electrosurgery and Leaflet Modification of the Valve
	Echo-Guided Interventions in Congenital Heart Disease
	LAA Occlusion: Present Insights and the Next Era
	Panel Discussion
17:40	Closing Remark

Time	Room B [Korean]
08:20-08:30	Opening and Course Introduction (In Room A)
08:30-09:50	The Tricuspid Valve in 360°: Measure, Guide, Judge
	Basic of Tricuspid Regurgitation: Anatomy, Pathophysiology, and Severity
	Multimodality Imaging for Tricuspid Regurgitation
	Functional TR: When to Intervene, When to Observe?
	Did It Deliver? RV Function and TR Evaluation After Intervention
	Panel Discussion
09:50-10:10	Coffee Break
10:10-11:20	Basic of Basic in T-TEER (English Session)
	Preprocedural Assessment and Patient Selection
	Basic of Intraprocedural TEE Imaging for T-TEER: The Must-Have Views You Cannot Miss
	Intraprocedural ICE Imaging: Essential Views Every T-TEER Needs
	Basic of Tricuspid TEER: Step-by-Step
	Panel Discussion
11:20-12:20	Nightmares in Structural Intervention
	My Unforgettable AV Intervention: The Case I Still Think About
	My Unforgettable Congenital Heart Disease Procedure: The Case I Still Think About
	My Unforgettable MV Intervention: The Case I Still Think About
	My Unforgettable Tricuspid Intervention: The Case I Still Think About
	Panel Discussion
12:20-13:30	Luncheon Session (Sponsored Session)
	Topic 1
	Topic 2
13:30-14:30	The Aortic Stenosis in 360°: Measure, Guide, Judge
	Aortic Valve Anatomy: What You Must Know
	Echo Cardiographic Measure, Interpret, And Decide. Are We Getting It Right?
	Reading TAVI CT from A to Z: What to Look For, What to Decide
	Follow-up of Prosthetic Aortic Valve: What to Look For, What to Do
	Panel Discussion
14:40-15:00	Coffee Break
15:00-16:00	Aortic Regurgitation in 360°: Measure, Guide, Judge
	Echo Cardiographic Measure, Interpret, Decide: When the Numbers Lie
	Multimodal Imaging for Aortic Regurgitation: Rvol Criteria of AR by CMR
	Up-to-Date Interventional Treatment of AR
	Up-to-Date Surgical Treatment of AR
	Panel Discussion
16:00-17:20	Plugging the Gap: Anatomy-Driven Device Selection
	LAAO Device Selection: Matching the Device to the Appendage
	ASD and VSD Closure: From Rim Deficiency to Device Choice
	Closing the PFO: Long Tunnel, Atrial Septal Aneurysm - Does the Device Change?
	Closing the PVL: Who Needs It, and How I Do It
	Panel Discussion
17:40	Closing Remark (In Room A)

Time	Room C [Korean]
08:20-08:30	Opening and Course Introduction (In Room A)
08:30-09:50	Diagnosing Cardiomyopathy: A Toolbox for Genetic and Acquired Disease
	Diagnosing Cardiac Sarcoidosis: Recognizing the Great Mimicker
	Management of Cardiac Sarcoidosis: Treatment and Follow-up
	Nuclear Imaging of Myocardial Inflammation
	Arrhythmogenic Cardiomyopathy: Imaging and Genetic Red Flags
	Panel Discussion
09:50-10:10	Coffee Break
10:10-11:50	Fabry Disease Across Asian Countries: A Multinational Perspective
	Fabry Disease in Japan: From the GLA Variant Spectrum to Current Practice
	Fabry Disease in Korea: Registry and Real-World Data
	Fabry Disease in Taiwan: Insights from National Cohort
	Fabry Disease in Japan: Prevalence and Screening Strategy
	Panel Discussion
12:20-13:30	Luncheon Session (Sponsored Session)
	Topic 1
	Topic 2
13:30-15:10	Fabry Disease: Basic Research Presentation
	siRNA Lipid Nanoparticles Ameliorate Fabry Disease Phenotype
	Intestinal Organoid of Fabry Disease
	Therapeutic Potential of Lomerizine on Fabry Vasculopathy
	Panel Discussion
15:10-16:50	Fabry Disease: Clinical Research Presentation
	Perifoveal Microvascular Alterations in Fabry Disease
	TBD
	Characterizing Audiological Profiles in Fabry Disease
	Current Treatment Status and Clinical Outcomes of Patients with FD
	Panel Discussion